Endovesical instillation of mitomycin-C in preventing recurrence of superficial bladder carcinoma.
It is now clear that MMC can be used as endovesical instillation after TUR, partial cystectomy or transurethral laser treatment and at the same time it has chemo-resection and chemoprophylactic efficacy. The success of treatment seems out of question on dosage but with the continuation of the instillation program. Recently, we have adopted 20 mg per instillation once every week for 40 times in the first year and once for 2-4 weeks for the second year, the overall recurrent rate was 17%. Such dosage used is more better than 2 mg, 10 mg or even 40 mg with acceptable side effects.
Wu
J J
JJ
Urological Dept., Ren Ji Hospital, Shanghai Second Medical University, China.
Yin
Z L
ZL
Zhu
J N
JN
D000283:Administration, Intravesical; D000328:Adult; D000368:Aged; D002295:Carcinoma, Transitional Cell / Q000473:pathology / Q000517:prevention & control*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage*; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000517:prevention & control*
D016685:Mitomycin